Cardiovascular prevention in diabetic patients: An evidenced-based review;Prevenção cardiovascular em pacientes com diabetes: Revisão baseada em evidências

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 51, Issue 2, 2007, Pages 312-318

  Furtado, Mariana Vargas ^b   Polanczyk, Carisi Anne ^a  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b NONE

Author keywords

Cardiovascular disease; Diabetes mellitus; Primary prevention

Indexed keywords

EID: 34248545330     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/s0004-27302007000200022     Document Type: Review

References (32)

1. Brasil. Ministério da Saúde. Secretaria de Políticas de Saúde. Departamento de Ações Programáticas Estratégicas. Plano de reorganização da atenção à hipertensão arterial e ao diabete melito: hipertensão arterial e diabete melito. Departamento de Ações Programáticas Estratégicas. Brasília: Ministério da Saúde, 2001. p. 104.
2. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al.; INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364:937-52.
3. Brasil. Ministério da Saúde. Secretaria de Políticas de Saúde. Departamento de Atenção Básica. Diabetes Mellitus/ Ministério da Saúde, Secretaria de Atenção à Saúde, Departamento de Atenção Básica. Brasília: Ministério da Saúde, 2006. p. 56.
4. IDF Clinical Guidelines Task Force. Global guideline for Type 2 diabetes. Brussels: International Diabetes Federation, 2005.
5. a ed. Porto Alegre: Artmed, 2004. p. 1577.
6. Brasil. Ministério da Saúde. Secretaria de Políticas de Saúde. Departamento de Atenção Básica. Prevenção clínica de doenças cardiovasculares e renais. Ministério da Saúde, Secretaria de Atenção à Saúde, Departamento de Atenção Básica. Brasília: Ministério da Saúde, 2006. p. 56.
7. Canadian Diabetes Association. Clinical Practice Guidelines Expert Commitee. Dyslipidemia in Adults with Diabetes. Can J Diabetes 2006;30(3):230-40.
8. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
9. Standards of Medical Care in Diabetes (Position Statement) - American Diabetes Association. Diabetes Care 2005;28(suppl 1):S4-36.
10. Consenso Brasileiro Sobre Diabetes - 2002. Diagnóstico e Classificação do Diabetes Melito e Tratamento do Diabetes Melito do Tipo 2. Sociedade Brasileira de Diabetes (SBD), 2002.
11. Risk assessment tool for estimating your 10-year risk of having a heart attack. National Heart, Lung and Blood Institute. Disponível em: 〈http://hin.nhlbi.nih.gov/atpiii/calculator. asp?usertype=pub〉. Acessado em: 26 julho 2003.
12. Estimating Coronary Heart Disease (CHD) Risk Using Framingham Heart Study Prediction Score Sheets. National Heart, Lung and Blood Institute. Disponível em: 〈http://www.nhlbi.nih.gov/about/framingham/risk- abs. htm〉. Acessado em: 12 setembro 2003.
13. Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, et al.; American Heart Association; American Diabetes Association. Primary Prevention of Cardiovascular disease in patients with diabetes. Diabetes Care 2007;30(1):162-72.
14. Singh RB, Dubnov G, Niaz MA, Ghosh S, Singh R, Rastogi SS, et al. Effect of an Indo-Mediterranean diet on progression of coronary artery disease in high risk patients (Indo-Mediterranean Diet Heart Study): a randomised single-blind trial. Lancet 2002;360:1455-61.
15. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jr. et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-72.
16. Intensive Blood Glucose Control With Sulphonylureas or Insulin Compared With Conventional Treatment and Risk of Complications in Patients With Type 2 Diabetes. UK Prospective Diabetes Study Group (UKPDS). Lancet 1998;352:837-53.
17. Hanefeld M, Fischer S, Julius U, Schulze J, Schwanebeck U, Schmechel H, et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996;39:1577-83.
18. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998;351:1755-62.
19. Orchard TJ, Forrest KY, Kuller LH, Becker DJ; Pittsburgh Epidemiology of Diabetes Complications Study. Lipid and blood pressure treatment goal for type 1 diabetes: 10-year incidence data from the Pittsburg Epidemiology of Diabetes Complications Study. Diabetes Care 2001;24:1053-9.
20. Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA, et al. Association of systolic blood pressure with macrovascular and microvascular complication of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000;321:412-9.
21. Tuomilehto J, Rastenyte D, Birkenhager WH, Thijs L, Antikainen R, Bulpitt CJ, et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med 1999;340:677-84.
22. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone. The Antihypertensive and Lipid- Lowering Treatment to prevent Heart Attack Trial (ALLHAT). JAMA 2000; 283:1967-75.
23. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-53.
24. Casas JP, Chua W, Loukogeorgakis S, Vallance P, Smeeth L, Hingorani AD, et al. Effect of inhibitors of the reninangiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 2005;366:2026-33.
25. a ed. Porto Alegre: Artmed, 2004. pp. 641-56.
26. Harris SB, Ekoé J-M, Zdanowicz Y, Webster-Bogaert S. Glycemic control and morbidity in the Canadian primary care setting (results of the diabetes in Canada evaluation study). Diabetes Res Clin Pract 2005;70:90-7.
27. MRC/BHF Heart Protection Study of cholesterol lowering with sinvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
28. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al.; CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial. Lancet 2004;364:685-96.
29. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al.; Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78.
30. Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS, et al. Sinvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001;345:1583-92.
31. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients. BMJ 2002;324:71-86.
32. Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002;136:161-72.